Juridical Foundation the Chemo-sero-therapeutic Research Institute

Kowa Company Limited

Sumiyo Takemoto

Hiroaki Maeda

Chikateru Nozaki

Yo Nakahara

Seiji Miyamoto

Toshihiro Nakashima

Masao Ohkuchi

Kazuyoshi Kaminaka

Tomoyuki Koshi

Toshiyuki Edano

Tsukasa Nishihara

Saburo Hara

Takumi Sasaki

Tsutomu Hamuro

Wataru Morikawa

Atsuko Sakata

Yuichi Kamikubo

A modified Staphylococcal enterotoxin B (SEB) having resistance to a protease and a reduced toxicity and a vaccine comprising said modified SEB are provided. A modified SEB which has an amino acid sequence as set forth in SEQ ID NO: 1 wherein each of the lysine at 97-position and the lysine at 98-position are substituted with any other amino acid, or a derivative thereof and a vaccine comprising said modified SEB or a derivative thereof.

Protease-resistant modified SEB and vaccine containing the same

A peptide comprising a peptide (A) of an amino acid sequence being abundant in basic amino acid residues and a peptide (B) of an amino acid sequence comprising at least two consecutive, hydrophobic amino acid residues wherein the peptide (B) is linked to the C-terminal of the peptide (A) directly or via several amino acid residues. The novel peptide of the present invention has the activity to inhibit growth of smooth muscle cells and a pharmaceutical composition comprising the peptide is useful for preventing or treating pathological conditions associated with growth of smooth muscle cells such as arteriosclerosis, restenosis after angioplasty, luminal stenosis after grafting blood vessel and smooth muscle sarcoma.

Peptide for inhibiting growth of smooth muscle cells

Neovascularization inhibitor containing tissue factor pathway inhibitor

Growing community of inventors

Kikuchi, Japan

Sumiyo Takemoto